EndoShape's Medusa Multicoil is used for the embolization, or blocking, of blood vessels. It’s used to close off vessels that might be ruptured and causing internal bleeding or vessels that are feeding a tumor.

EndoShape secures more than $14 million in funding

BOULDER — EndoShape, a medical device company that makes polymer vascular plugs and coils, recently closed on more than $14 million in funding, according to a Form D filed with the Securities and Exchange Commission.

EndoShape’s flagship product, the Medusa MultiCoil, is a device used for the embolization, or blocking, of blood vessels. It’s used to close off vessels that might be ruptured and causing internal bleeding or vessels that are feeding a tumor.

The Boulder company filed an amendment on March 21 to a form filed in February 2016 for equity offered. About $10.49 million was sold.

When the company originally filed on February 10 last year, it was offering $9.9 million in equity and had sold $7 million.

In February of this year, EndoShape filed another new notice with the date of first sale on Jan. 23, 2017. The company was offering $6 million in equity and had sold just less than $4 million.

When EndoShape amended last year’s filing on Tuesday, the company noted that it had sold all of its offering amount.

EndoShape did not immediately respond to requests for comment.

 

BOULDER — EndoShape, a medical device company that makes polymer vascular plugs and coils, recently closed on more than $14 million in funding, according to a Form D filed with the Securities and Exchange Commission.

EndoShape’s flagship product, the Medusa MultiCoil, is a device used for the embolization, or blocking, of blood vessels. It’s used to close off vessels that might be ruptured and causing internal bleeding or vessels that are feeding a tumor.

The Boulder company filed an amendment on March 21 to a form filed in February 2016 for equity offered. About $10.49 million was sold.

When the company originally filed on February 10 last year, it was offering $9.9 million in equity and had sold $7 million.

In February of this year, EndoShape filed another new notice with the date of first sale on Jan. 23, 2017. The company was offering $6 million in equity and had sold just less than $4 million.

When EndoShape amended last year’s filing on Tuesday, the company noted that it had sold all of its offering amount.

EndoShape did not immediately respond to requests for comment.